Allianz Asset Management’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.29M Buy
700,516
+250,728
+56% +$2.09M ﹤0.01% 1235
2025
Q4
$3.74M Buy
449,788
+257,628
+134% +$2.77M ﹤0.01% 1269
2025
Q3
$2.8M Buy
+192,160
New +$2.3M ﹤0.01% 1364
2024
Q2
Sell
-34,712
Closed -$1.61M 2148
2024
Q1
$1.61M Buy
34,712
+6,884
+25% +$356K ﹤0.01% 1260
2023
Q4
$1.88M Hold
27,828
﹤0.01% 1354
2023
Q3
$2.01M Hold
27,828
﹤0.01% 1433
2023
Q2
$2.07K Buy
27,828
+5,000
+22% +$296K ﹤0.01% 2019
2023
Q1
$1.21M Buy
22,828
+5,922
+35% +$375K ﹤0.01% 1611
2022
Q4
$1.14M Hold
16,906
﹤0.01% 1463
2022
Q3
$2.11M Buy
+16,906
New +$2.01M ﹤0.01% 1215

Other funds holding DNA

Allianz Asset Management's DNA Position: Q1 2026 in Review

Allianz Asset Management increased its Ginkgo Bioworks (DNA) stake by 56% in Q1 2026, buying an estimated $2.09M and bringing the position to 700,516 shares worth $4.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Allianz Asset Management first reported a position in DNA in Q3 2022 and has held it in 10 quarters since. 174 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

  • Allianz Asset Management held 700,516 shares of Ginkgo Bioworks worth $4.29M as of Q1 2026.
  • Allianz Asset Management bought 250,728 Ginkgo Bioworks shares in Q1 2026, an estimated $2.09M.
  • Ginkgo Bioworks made up ﹤0.01% of Allianz Asset Management's portfolio in Q1 2026, its #1235 holding.
  • Allianz Asset Management first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 10 quarters since.
  • 174 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.